Biocon and Medix sign semi-exclusive distribution deal for Liraglutide (gSaxenda) in Mexico.
Biocon Ltd and Mexico-based Medix signed a semi-exclusive distribution and supply agreement for Biocon's Liraglutide (gSaxenda) drug, used for chronic weight management. Biocon will handle approval, manufacturing, and supply while Medix commercializes the drug in Mexico, aiming to provide affordable access and improve obesity patients' quality of life. The total addressable market opportunity is $37M.
May 13, 2024
4 Articles